Bisphosphonates in patients with multiple myeloma (MM) reduces pathological vertebral fractures, skeletal-related events, and pain, according to a Cochrane review of 24 trials involving nearly 7,300 participants. Among the findings:
- Bisphosphonates did not improve overall or disease progression-free survival.
- They reduced overall fractures and fractures of the vertebra, but not non-vertebral fractures.
- They alleviated pain, with osteonecrosis the only major adverse event (event rate of 1/1,000 patients treated).
- Zoledronate was more efficacious than than etidronate and placebo, but it did not improve overall survival or other outcomes better than pamidronate or clodronate.
- No specific aminobisphosphonate or non-aminobisphosphonate was found to be superior for any outcome.
Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Bisphosphonates in multiple myeloma: An updated network meta-analysis. Cochrane Database of Systematic Reviews. 2017, Issue 12. Art. No.: CD003188. doi:10.1002/14651858.CD003188.pub4
This Week's Must Reads
Must Reads in Leukemia, Myelodysplasia, Transplantation
CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9
Cochrane on Bisphosphonates in Multiple Myeloma, Cochrane; 2017 Dec 18; Mhaskar, Kumar, et al
Venetoclax Regimens Assessed in Patients with AML, Am J Hematol; ePub 2017 Dec 23; DiNardo, et al
Encourage This Behavior in Childhood ALL Survivors, Cancer; ePub 2017 Dec 4; Howell, Wilson, et al
Prognostic Testing Patterns, CLL Outcomes Assessed, Clin Lymphoma Myeloma Leuk; ePub 2017 Dec 5; Mato, et al